In metastatic colorectal cancer (mCRC), there is now a desire to prolong overall survival (OS) by using individualized therapeutic strategy and minimal toxicity. This study was conducted to assess the efficacy and safety of the use of maintenance low dose capecitabine, an oral fluoropyrimidine carbamate that proved efficacy in treatment of advanced colorectal cancer, after best response achieved with previous standard chemotherapy. Methods: This is a prospective study, conducted on 40 colorectal cancer patients with irresectable metastasis, after achieving objective response with standard chemotherapy. Capecitabine was given at a dose of 500 mg/m 2 (maximum 1000 mg total) twice daily for 5 days/week continuously till progression or unacceptable toxicity. Evaluation was done every 3 cycles or earlier in case of suspected progression. Adverse events, progression free survival (PFS), and survival follow-up data were collected. Results: The study regimen proved to be quite tolerable. Main toxicities were hand-foot syndrome (60%) and fatigue (50%). Only 7.5% developed grade III hand-foot syndrome. The median time to progression was 34 weeks. Overall survival was 65.2% and 59.8% at one and two years respectively. Synchronous metastasis had a significant negative impact on PFS in comparison to metachronous metastases. Better performance status and good objective response to previous chemotherapy had significant positive impact on both PFS and OS.
INTRODUCTION
Advances have been made over the past decade in the treatment of metastatic colorectal cancer (mCRC), where there is significant increase in response rate as well as increase in the median survival from 5 months to 2 years, as a result of advances in surgical techniques, newer options in chemotherapy and the emergence of effective biotherapy 1 .Given patients' preferences for more tolerable regimens and improved quality of life, treatment approaches have changed from continuous high-dose aggressive therapy until disease progression to either chemotherapy-free intervals or reduced-dose, lesstoxic maintenance regimens 2, 3 .
Maintenance therapy refers to the close, regular administration of a chemotherapeutic drug at relatively low (non-toxic) doses, over prolonged periods, with no extended drug-free break periods 4 . The main targets of continuous chemotherapy are the endothelial cells of the growing vasculature of a tumor 4 . Maintenance therapy can be integrated and sequenced with standard maximum tolerated dose type chemotherapy where brief courses of such induction therapy, given 'upfront', is followed by long term maintenance low-dose chemotherapy, or combined with a concurrent targeted therapy, especially antiangiogenic drugs such as anti -vascular endothelial growth factor receptor (VEGFR) -2 antibodies 5 .
Among the advantages of maintenance chemotherapy is reduction in acute toxicities, hospital admission costs and increased patient's convenience. This can be done by using oral drugs that can be taken at home 6 . Several trials are being performed to evaluate the efficacy, safety and quality of life through the use of maintenance therapy in advanced colorectal cancer, using many agents like irinotecan 7 , infusion fluorouracil (5-FU) 8 and oral fluoropyrimidines [9] [10] [11] [12] [13] [14] [15] , as well as targeted therapy like bevacizumab and erlotinib [32] [33] [34] [35] [36] .
Capecitabine is an oral 5-FU prodrug that is modified via a different metabolic pathway than other oral 5-FU derivatives. Compared to intravenous 5-FU, capecitabine is associated with a lower incidence and severity of diarrhea, stomatitis, nausea, and neutropenia but an increased rate of hand-foot syndrome (HFS) 12 . Its high concentration in tumor tissue increases both the efficacy and tolerability of the agent through targeted delivery. Its oral administration simplifies care, frequently precluding the need for central venous access or infusion pumps 16 .
Compared to other oral 5-FU derivatives such as S-1 and tegafur-uracil, capecitabine is approved by the United States Food and Drug Administration (FDA) and has been extensively studied in gastrointestinal malignancies. Capecitabine has been shown to be a safe and efficacious alternative to bolus 5-FU for mCRC in phase III clinical trials 17, 18 .
Several clinical trials are currently under way which will help to further elucidate the role of chemo-holidays with periods of low dose maintenance therapy on patient outcome and quality of life in the era of the routine use of conventional chemotherapy plus targeted agents as first-line standard of care.
The aim of this study was to assess the efficacy and safety of the use of maintenance low dose capecitabine, after best response achieved with previous standard chemotherapy in mCRC patients with irresectable metastasis. 
PATIENTS AND METHODS

Study design
Patient population
Inclusion criteria included irresectable mCRC with expected survival of more than 3 months. The age included is above 18 years with Eastern Cooperative Oncology Group (ECOG) performance status of 0 -2, 19 and adequate bone marrow, renal and liver functions. Patients had to achieve objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 20 after one or more of standard chemotherapy regimens for metastatic disease with at least one bidimensionally measurable lesion by computerized tomography (CT) and/or magnetic resonance imaging (MRI) at the initiation of standard chemotherapy. The interval between completion of the former chemotherapy regimen and starting capecitabine should not exceed 4 weeks.
Exclusion criteria included tumor progression before recruitment, ascites or pleural effusions as the only assessable lesions, planned radical resection of metastatic disease and symptomatic cerebral metastases. Any other concurrent severe or uncontrolled diseases that may significantly impair the absorption or affect the tolerance of the oral drug were excluded. These included history of dihydropyrimidine dehydrogenase deficiency (DPD), uncontrolled gastrointestinal disease (e.g nausea, vomiting, diarrhea, malabsorption syndrome, or bowel obstruction) and pregnancy.
Pretreatment evaluation
Medical history, clinical examination, complete blood picture, complete liver and kidney function tests, baseline serum carcinoembryonic antigen (CEA) level, electrocardiography (ECG), CT scan and/or MRI (baseline evaluation according to sites of metastases).
Treatment plan
Capecitabine was given at a dose of 500 mg/m 2 (with a maximum of 1000 mg total dose) twice daily for 5 days/week, administered orally one hour after breakfast and evening meals. The dose was calculated according to body surface area, however, the majority of patients had received the maximum dose of 1000 mg twice daily (2 Tablets bid). It was given continuously till either disease progression or unacceptable toxicity.
In the event of patients developing drug-related grade 3 adverse events, laboratory abnormalities, or in patients in whom the investigator judged continuation of treatment unfeasible, treatment was delayed for up to 4 weeks to allow patient recovery.
When continuation of treatment at the same dose considered being intolerable due to adverse events, irrespective of grade, the drug was administered with 25% dose reduction.
Treatment was permanently discontinued in case of persistent drug intolerability, even after dose reduction and transient discontinuation.
Study assessment
One treatment cycle was defined as a 4-week treatment. Complete blood counts were repeated every 2 weeks, and biochemical tests were done every 4 weeks.
Symptoms were followed and regular clinical staging was performed every 3 cycles using CT scan and/or MRI and serum CEA level. Evaluation was done earlier in the case of clinical progression.
Adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events -version 3 (CTCAE v3.0) 21 every cycle.
Evaluation of efficacy
Maintenance of the tumor response was evaluated every 3 cycles or earlier in case of suspected progression. Response of previous chemotherapy as well as current study treatment was measured according to RECIST criteria. 20 Progression free survival (PFS) was calculated from the date of study entry until objective tumor progression or death. Overall survival (OS) was calculated from the date of study entry until the last follow up visit or death.
Evaluation of safety
Safety was evaluated in all patients who received Capecitabine treatment, and adverse event frequencies were recorded and graded in accordance with the CTCAE v3.0. 21 . HFS (or palmar-plantar erythrodysesthesia) was classified as grade 1, painless mild skin changes; grade 2, pain or skin changes including peeling, blisters, bleeding, edema not affecting daily function; grade 3, painful skin changes affecting daily function 22 .
Statistical analysis
Kaplan-Meier Survival Analysis was used to examine the distribution of time-to-event variables and to compare the distribution by levels of a factor variable or produce separate analyses by levels of a stratification variable. Log rank test was used to compare time-toevent variables by levels of a factor variable.
RESULTS
Patients charecteristics
Patients' baseline characteristics are shown in (Table 1) Forty patients were recruited, with median age of 51 years ranging from 29 to 75 years (24 female and 16 male), ECOG performance status from 0 to 2, all patients had colorectal cancer (29 colon, 11 rectal) with unresectable metastases (synchronous metastases in 27 patients and metachronous metastases in 13 patients) where 29 patients had 1 metastatic site, 10 had 2 and 1 had 3 metastatic sites.
Thirty one patients underwent previous surgery (24 to primary, 4 to secondary, 3 to both), 6 patients had received prior radiotherapy, and all patients had received one (15 patients) or more chemotherapy lines (25 patients) for metastatic disease. Response of previous chemotherapy (before the current study) was: CR in 10 patients (25%), PR in 2 patients (5%) and SD in 28 patients (70%).
Treatment duration and outcome
The median duration of treatment was 34 weeks with standard of error of 4.096 weeks (ranging from 4 to 86 weeks). The mean number of cycles received was 7.5 cycles ±5.1 as standard of deviation, ranging from 1 to 21.5 cycles. The median follow up interval was 12 months ranging from 1 to 30 months.
Out of 40 patients recruited in this study, 35 patients (87.5%) developed disease progression, while the study was terminated in 2 patients (5%) for toxicity, and 3 patients (7.5%) for unrelated medical or surgical conditions.
By the end of the study, 26 patients (65%) were still alive, while 14 patients (35%) died. Table 2 shows the frequency of adverse events. No grade 4 toxicities were detected during the use of low dose capecitabine. Grade III was detected in only 3 patients (7.5%) who developed grade III HFS. Nonhematological toxicities in the current study included: HFS (60%), fatigue (50%), anorexia (32.5%), abdominal pain (31.5%), diarrhea (22.5%), hyperbilirubinemia (17.5%), mucositis (17.5%), nausea (5%), and vomiting (5%). Hematological toxicities were neutropenia (17.5%), anemia (12.5%), and thrombocytopenia (5%). The response to previous chemotherapy was also associated with significant difference in PFS (p value= 0.05). Mean PFS for patients who had achieved CR or PR was 53.7 weeks (95% CI: 33.5 -73.9), while the mean PFS for patients who had achieved SD was 31.4 weeks (95% CI: 21.8 -41).
Safety
Treatment compliance
Difference in PFS was not significant between patients ≤ 50 years of age or above, colon versus rectum as a primary site, number of metastatic sites, previous surgery to secondaries, or number of previous chemotherapy lines received.
One year survival was 65.2%, and the estimated 2 years survival is 59.8%, with significant difference between patients with different performance status (p value= 0.021) and response achieved with previous chemotherapy (p value= 0.021).
Kaplan-Meier curves for PFS and OS are shown in Figures 1 and 2 , respectively.
Further management after study termination
After study termination, 23 patients (57.5%) received standard palliative chemotherapy for metastatic disease, 1 patient (2.5%) received palliative chemo-radiation (for recurrent rectal mass), 1 patient (2.5%) underwent palliative surgery (for recurrent obstructing colonic mass), while 15 patients (37.5%) have undergone no further management (best supportive care). A big portion of patients in a palliative setting, will have no or only mild symptoms from their metastatic disease. In these patients, the main goals of therapy are extending PFS and maintaining the quality of life as long as possible. These patients will benefit from a careful long-term strategic planning of treatment sequences with mindful attention to treatment toxicities 23 . This mandates changes in therapy schedule, with treatment breaks or phases of less-intensive maintenance therapy interspersed with periods of more-intensive therapy to control tumor progression. This conceivably reduce the cumulative toxicities of therapy, potentially prevent the unplanned, premature discontinuation of therapy, preserve the ability to administer further phases of therapy, potentially maximize the time on therapy, reduce cost, and could increase quality of life for patients. One agent can be efficacious when used in various sequential phases of therapy 24 .
Maintenance capecitabine at low doses has been applied successfully in a number of small clinical trials. However, an effective dose of metronomic capecitabine has not been established; doses from 500 to 2,000 mg daily can be found in the literature 25 .
In the current study, the median PFS was 34 weeks (7.9 months) which is comparable to that achieved with combination chemotherapy using oxaliplatin plus either 5-FU or capecitabine, as well as irinotecan plus 5-FU that expected to achieve a PFS of 7 to 9 months [26] [27] [28] .
Regarding the safety profile in the current study, no grade 4 toxicities were detected during the use of low dose capecitabine. Grade III was detected in only 3 patients (7.5%) who developed grade III HFS. In contrast, the incidence of grade 3 HFS with standard dosing of capecitabine ranges from 16% to 44%.
Toxicity was the cause of study termination in only 2 patients (5%), while the third improved after treatment delay and dose reduction. This is also in contrast to standard-dose capecitabine, which is associated with a 13% discontinuance rate due to side effects 31 .
This toxicity profile was comparable to number of studies that evaluated the safety of use of low dose capecitabine in advanced GI malignancies 3, 8, 12 .
Results of the current study encourages the usage of the low dose capecitabine in minimally pretreated patients to maintain their response reserving more chemotherapy lines to subsequent stages, gaining time and better performance by reducing toxicity.
Ongoing clinical trial is testing maintenance chemotherapy with capecitabine versus control after best response with first line chemotherapy in advanced colorectal cancer, where the main endpoint is PFS 32 .
It is conceivable that the strength of biologics could well lie in being used as maintenance therapy after induction of response using conventional chemotherapy. This approach has shown success in the MACRO trial 33 . Also it is being tested in ongoing clinical trials 34, 35 .
CONCLUSION
Maintenance low dose capecitabine may be effective in maintaining response in patients with mCRC patients with good tolerability.
This regimen should be further explored in larger prospective randomized controlled studies to demonstrate efficacy in mCRC as a maintenance therapy in minimally pretreated patients reserving more chemotherapy lines to subsequent stages. The usage of maintenance capecitabine could also be an option instead watchful waiting in the stable heavily pretreated mCRC cases.
